 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...5253545556575859606162...235236» |
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Development and evaluation of 5FUCore, OxaliCore, and IrinoCore transcriptomic signatures for predicting response to individual drugs in the FOLFIRINOX regimen: Towards toxicity reduction and personalized chemotherapy in PDAC. (Available On Demand; Poster Bd # 462) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1267;
The signatures developed provide a tool for predicting responsiveness to the individual therapeutic drugs of the FFX regimen. They may ultimately lead to the development of a personalized strategy for combined chemotherapy regimens, increasing efficacy and reducing toxicity in PDAC.
- mitazalimab (ADC-1013) / Alligator Biosci
Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study. (Available On Demand; Poster Bd # 460) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1265;
P1b/2
Mitazalimab + mFOLFIRINOX is a feasible regimen with a manageable safety profile. Mitazalimab administered at 900
- 5-fluorouracil / Generic mfg.
Efficacy and safety of HepaSphere drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. (Available On Demand; Poster Bd # 443) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1249;
All of the observed PFS, OS, ORR and DCR in Hepa-HAIC group are superior to HAIC group, which indicates the combination of HepaSphere DEB-TACE and HAIC may lead to improved outcomes with comparable safety profile in advanced HCC. >
- Opdivo (nivolumab) / Ono Pharma, BMS, Rubraca (rucaparib) / Clovis
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02. (Available On Demand; Poster Bd # 434) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1240;
P2
Exploratory endpoint of association of genomic analysis with efficacy is ongoing and will be discussed. Clinical trial information: NCT03639935.
- BOLD-100 / Bold Therap, Intezyne
BOLD-100-001 (TRIO039): A phase 1b/2a study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pre-treated advanced gastric and biliary tract cancer: Efficacy and safety analysis. (Available On Demand; Poster Bd # 419) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1226;
P1b/2a
There were no new safety signals. The preliminary mPFS, mOS, ORR and DCR data in this interim analysis demonstrate significant improvement over the currently available therapies for these difficult to treat advanced GI cancers.
- Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis. (Available On Demand; Poster Bd # 415) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1222;
In portal invasion and extrahepatic metastasis subgroups, HAIC-FO may be a preferred option, with sorafenib combined with FOLFOX as an additional option in those with HBV infection. Besides, novel combination therapy should be focused on in patients with certain subgroups.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean Cancer Study Group, and the Dutch Upper GI Cancer group. (Available On Demand; Poster Bd # 378) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1186;
P2
However, CT+T showed interesting response rates, especially with FLOT as CT backbone. Follow-up data including survival is necessary to define the clinical value of this regimen.
- Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Modified FOLFOX plus/minus nivolumab and ipilimumab vs FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: The randomized phase 2 IKF-S628 Moonlight trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). (Available On Demand; Poster Bd # 371) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1179;
P2
a) Chemo plus dual checkpoint inhibition administered in parallel is associated with an increase in toxicity but not activity. b) Although associated with lower toxicity the use of sequential chemo followed by IO monotherapy is insufficient.
- Opdivo (nivolumab) / Ono Pharma, BMS
FLOT plus nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Results from the randomized phase 2 IKF-S628/AIO-STO-0417 (Moonlight) trial of the AIO. (Available On Demand; Poster Bd # 366) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1174;
P2
FLOT plus nivo may represent an option for select patients with aggressive, rapidly progressive disease. Clinical trial information: NCT03647969.
- Cyramza (ramucirumab) / Eli Lilly
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy within the prospective phase II IKF-S628/AIO-STO-0417 (MOONLIGHT) trial. (Available On Demand; Poster Bd # 364) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1172;
P2
Sequential angiogenesis inhibition with anti-VEGFR-2 targeting therapy following immunochemotherapy might be a promising option to overcome resistance to immunotherapy, which warrants further investigations in a larger cohort. Clinical trial information: NCT03647969.
- zolbetuximab (IMAB362) / Astellas
Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW). (Available On Demand; Poster Bd # 356) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1164;
P3
CLDN18.2 prevalence was 43.7% (513/1175) in female pts and 36.9% (886/2401) in male pts. CLDN18.2 prevalence was 44.0% (671/1524) in pts in Europe/Middle East, 37.7% (183/485) in pts in N. America, and 36.5% (479/1314) in pts in Asia Pacific.
- Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial. (Available On Demand; Poster Bd # 348) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1157;
P2
Further analysis of baseline clinical and molecular data to better identify the subgroup of patients benefitting the most of trastuzumab/nivolumab/ipilimumab will be presented at the meeting. Clinical trial information: NCT03409848.
- Opdivo (nivolumab) / Ono Pharma, BMS
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. (Available On Demand; Poster Bd # 347) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1156;
P3
Clinical trial information: NCT02872116. >aper BICR.
- Tukysa (tucatinib) / Seagen, Herceptin (trastuzumab) / Roche
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study. (Available On Demand) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1152;
P2
The observed antitumor activity supports the combination of TUC and Tras as a future chemotherapy-free treatment option for this population with historically poor outcomes. Clinical trial information: NCT04579380.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial. (Available On Demand) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1151;
P2, P3
The NALIRIFOX safety profile was consistent with the profiles of the regimen components and generally manageable. Clinical trial information: NCT04083235.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1). (Available On Demand) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1150;
P2/3
Our results do not support neoadjuvant chemotherapy as standard of care for these patients. Future trials should incorporate a biomarker-based design.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Biomarker, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study. (Pubmed Central) - Apr 26, 2023
The digital evaluation of tumor immune cell infiltrate by means of Immunoscore-IC or Immunoscore identifies the subset of patients with pMMR mCRC achieving more benefit from the addition of the anti-PD-L1 to the upfront treatment. Immunoscore-IC stands as the most promising predictor of benefit from ICIs.
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab (clinicaltrials.gov) - Apr 26, 2023
P1, N=10, Recruiting, Sponsor: Anne Noonan
Immunoscore-IC stands as the most promising predictor of benefit from ICIs. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial completion date, Trial primary completion date: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Apr 26, 2023
P3, N=757, Active, not recruiting, Sponsor: Takeda
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Apr 2023 --> Mar 2024 | Trial primary completion date: Apr 2023 --> Mar 2024
- | Enrollment closed, Metastases: New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study (clinicaltrials.gov) - Apr 26, 2023
P2, N=105, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Apr 2023 --> Mar 2024 | Trial primary completion date: Apr 2023 --> Mar 2024 Not yet recruiting --> Active, not recruiting
- |||||||||| Avastin (bevacizumab) / Roche
New P3 trial: Repeat local treatment +/- neoadjuvant systemic therapy for recurrent colorectal liver metastases. Lokale behandeling +/- neoadjuvant systemische therapie voor recidieven van leveruitzaaiingen van dikke- en endeldarmkanker. (EUDRACT) - Apr 25, 2023
P3, N=360, Ongoing, Sponsor: Amsterdam University Medical Centers
- | 5-fluorouracil / Generic mfg.
Observational data, Journal: Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study. (Pubmed Central) - Apr 25, 2023
The majority of patients received suboptimal doses of 5-FU using BSA dosing. Therapeutic drug monitoring of 5-FU is an option for optimized individualized cancer therapy and should be integrated into the clinical practice.
- ||| Yutuo (zimberelimab) / Arcus Biosci, Gilead, quemliclustat (AB680) / Arcus Biosci, Gilead
Enrollment open, Combination therapy, Metastases: Zimberelimab and Quemliclustat in Combination with Chemotherapy for the Treatment of Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 25, 2023
P1/2, N=56, Recruiting, Sponsor: Jonsson Comprehensive Cancer Center
Therapeutic drug monitoring of 5-FU is an option for optimized individualized cancer therapy and should be integrated into the clinical practice. Not yet recruiting --> Recruiting
- Comprehensive genomic profiling of tumor tissue and plasma-circulating tumor DNA in RAS/BRAFV600E wild type metastatic colorectal cancer patients: Initial findings from the CAPRI 2-GOIM trial (Auditorium B, Level 0) - Apr 24, 2023 - Abstract #ESMOGI2023ESMO_GI_152;
P2
Both tumor tissue- and liquid biopsy-based comprehensive genomic profiling by NGS identify additional molecular alterations, that could be involved in resistance to anti-EGFR monoclonal antibodies, as compared to PCR-based tumor tissue analysis. CAPRI 2-GOIM trial will determine if NGS would allow better selection of RAS/BRAFV600E WT mCRC patients for the most appropriate treatments through three sequential lines of therapies.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial (Auditorium A, Level 0) - Apr 24, 2023 - Abstract #ESMOGI2023ESMO_GI_21;
P2, P3
The NALIRIFOX safety profile was consistent with the profiles of the regimen components and generally manageable. These results support the NALIRIFOX regimen as a new reference regimen for the first-line treatment of patients with mPDAC.
- || Clinical, Journal, Metastases: The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study. (Pubmed Central) - Apr 24, 2023
In our study, FFX regimen provides a significant advantage over the other treatment regimens in terms of response rates and survival. Treatment toxicity was more frequent but manageable with the FFX regimen.
- Vectibix (panitumumab) / Amgen, Takeda
Ultraviolet Recall Phenomenon in a Patient with Metastatic Rectal Cancer (Level 3 - Room 320) - Apr 24, 2023 - Abstract #WCD2023WCD_3233;
BACKGROUND: UV recall is a rare photodermatitis that can occur in previously UV-injured skin after the administration of systemic medications including methotrexate and antibiotics...She had been on FOLFIRI chemotherapy regimen (i.e., folinic acid, 5-fluorouracil, and irinotecan) and panitumumab for her rectal cancer over one year with last treatments given two and six weeks ago, respectively...Photo-distribution of the eruption, prior history of UV-exposure over the same area along with histologic findings of epidermal necrosis without cellular atypia are the key for diagnosis. Topical corticosteroids can help manage the rash while continuing the causative medications if needed
- Humira (adalimumab) / Eisai, AbbVie
Polyarteritis nodosa reveals cerebral toxoplasmosis in an immunocompromised patient (Level 3 - Room 327) - Apr 24, 2023 - Abstract #WCD2023WCD_3100;
Because of extracutaneous sarcoidosis, she was under triple immunosuppression with methotrexate, adalimumab and prednisolone...Treatment with clindamycin, pyrimethamine and folinic acid was initiated...Toxoplasmosis should be considered as an infectious cause of cutaneous vasculitis. Extreme caution should be taken in cases of severe immunosuppression
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: If we are worried about SCRT, Good reason to open and enroll patients to The JANUS #Rectalcancer trial at your centers TnT: LCRT followed by randomization to FOLFOX/CAPOX or FOLFIRINOX in low, T4N0, and anyTN+ rectal cancers #crcsm @theNCI @ALLIANCE_org @JoshSmithMDPhD (Twitter) - Apr 23, 2023
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Young with ECOG 0. Cape per BILCAP (as @MPishvaian also pointed out) would be reasonable. But with close margins and high recurrence rate (local and distal), would XRT help? Should this be treated as pancreatic initially (FOLFIRINOX x 4-6 cycles and then add Cape - XRT)? (Twitter) - Apr 23, 2023
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Efficacy of Second Line FOLFIRI in Locally Advanced and Metastatic Biliary Tract Cancer: A Retrospective Study () - Apr 21, 2023 - Abstract #CCF2023CCF_165;
- | Trial completion date, Trial primary completion date: Colon Neoadjuvant FOLFOXIRI Study (clinicaltrials.gov) - Apr 21, 2023
P2, N=40, Active, not recruiting, Sponsor: Chinese University of Hong Kong
Extreme caution should be taken in cases of severe immunosuppression Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
- | Avastin (bevacizumab) / Roche
Trial completion date, Trial primary completion date: ORCHESTRA: Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases (clinicaltrials.gov) - Apr 21, 2023
P=N/A, N=478, Recruiting, Sponsor: Radboud University Medical Center
Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2022 --> Jul 2023
- |||| Clinical: Zolbetuximab plus mFOLFOX6 in patients with #CLDN18.2-positive, unresectable #gastriccancer or #esophagealcancer (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial @mdmanishshah @WCMGIcancer https://t.co/DDbaBVaWx0 (Twitter) - Apr 20, 2023
- | Journal, Metastases: Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy. (Pubmed Central) - Apr 20, 2023
The new protocol (FLOT, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel), included patients with resectable GEJ and gastric cancer who had a clinical stage cT or higher nodal positive cN+ disease (Group 2)...The rate of side effects was also appreciably lower following the FLOT protocol. These results strongly suggest a significant advantage of the FLOT neoadjuvant treatment used before surgery.
- | Avastin (bevacizumab) / Roche, Kaitanni (cadonilimab) / Akesobio
New P2 trial: AK104-IIT-C-N-0052: HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 20, 2023
P2, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- ||| certepetide (LSTA1) / Lisata Therap
Enrollment open: BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 20, 2023
P2a, N=120, Recruiting, Sponsor: Lisata Therapeutics, Inc.
These results strongly suggest a significant advantage of the FLOT neoadjuvant treatment used before surgery. Not yet recruiting --> Recruiting
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical: 🎥 @JoeHermanMD of @NorthwellHealth talks on the Alliance trials: Combination of modified FOLFIRINOX and radiotherapy for pancreatic cancer Watch: 👉https://t.co/X5dasi80tN👈 @GreatDebatesCME #GDUGI2023 #PancSM (Twitter) - Apr 19, 2023
- | Tyvyt (sintilimab) / Eli Lilly
Trial completion date, Metastases: TAIPD1-HCC: HAIC Combined With PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC (clinicaltrials.gov) - Apr 19, 2023
P2, N=40, Active, not recruiting, Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting Trial completion date: Dec 2022 --> Dec 2024
- | leucovorin calcium / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant (clinicaltrials.gov) - Apr 19, 2023
P2, N=46, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Dec 2022 --> Dec 2024 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- || BI 905711 / Boehringer Ingelheim
Enrollment change, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Apr 19, 2023
P1a/1b, N=13, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 N=10 --> 13
- | Trial completion, Surgery: Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (clinicaltrials.gov) - Apr 19, 2023
P2, N=130, Completed, Sponsor: Medical College of Wisconsin
N=10 --> 13 Unknown status --> Completed
- irinotecan / Generic mfg.
IRINOTECAN INDUCED TRANSIENT DYSARTHRIA: A CASE SERIES (Regency Ballroom A/B (second floor)) - Apr 18, 2023 - Abstract #CSCTRMWAFMR2023CSCTR_MWAFMR_173;
It is also an alternative treatment in metastatic gastric cancer if cisplatin is not tolerated...There have been approximately 50 cases described in the literature to date. The goal of this article is to add to the growing volume of similar cases and call to attention the importance of shared decision making with patients.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Surgery, Metastases: PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery (clinicaltrials.gov) - Apr 18, 2023
P2/3, N=1194, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
The goal of this article is to add to the growing volume of similar cases and call to attention the importance of shared decision making with patients. Trial primary completion date: Jun 2023 --> Dec 2022
- | New P3 trial, Circulating tumor DNA: ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer (clinicaltrials.gov) - Apr 18, 2023
P3, N=490, Recruiting, Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- || BI 905711 / Boehringer Ingelheim
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers (clinicaltrials.gov) - Apr 18, 2023
P1a/1b, N=10, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Jun 2023 --> Dec 2022 Recruiting --> Active, not recruiting | N=100 --> 10 | Trial completion date: Nov 2024 --> Sep 2023 | Trial primary completion date: Jun 2024 --> Sep 2023
- ||||| Opdivo (nivolumab) / BMS
Trial completion, Trial completion date: CheckMate 9X8: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (clinicaltrials.gov) - Apr 18, 2023
P2/3, N=196, Completed, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting | N=100 --> 10 | Trial completion date: Nov 2024 --> Sep 2023 | Trial primary completion date: Jun 2024 --> Sep 2023 Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Dec 2022
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
P2 data, Journal, Metastases: The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-na (Pubmed Central) - Apr 18, 2023
P2
The GIANT study is the first randomized, prospective national trial evaluating vulnerable OA with mPCA aimed at developing a tailored treatment approach for this patient population. This trial has the potential to establish a new way of objectively selecting vulnerable OA with mPCA for modified treatment and to establish a new standard of care in this growing patient population.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
@DrAhmedAlShehri دكتور الله يسعدك هل هذا النوع من الكيماوي يتجيب بنسبه كبيره ام لا ؟. FOLFIRINOX (Twitter) - Apr 17, 2023
- |||| Clinical, Metastases: Zolbetuximab (mAb to claudin-18 isoform 2 [CLDN18.2])+mFOLFOX6 vs placebo+mFOLFOX6 for prev untreated CLDN18.2+ve, HER2-ve locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ✅PFS HR 0·75 (95% CI 0·60–0·94) ✅OS 0·75 (0·60–0·94) @KoheiShitara @OncoAlert (Twitter) - Apr 17, 2023